Sasanlimab is under clinical development by Pfizer and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According to GlobalData, Phase I drugs for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sasanlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sasanlimab (PF-06801591) is under development for the treatment of non muscle invasive bladder cancer, sarcoma, metastatic melanoma, muscle invasive bladder cancer, head and neck cancer squamous cell carcinoma, non-small cell lung cancer, urothelial carcinoma, ovarian cancer and other solid tumors. The drug candidate is administered intravenously and subcutaneously. The drug candidate is a monoclonal antibody which targets programmed cell death protein1 (PD-1). The drug candidate is a new molecular entity.
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Sasanlimab’s drug-specific PTSR and LoA scores, buy the report here.